Results 171 to 180 of about 10,221 (208)
Some of the next articles are maybe not open access.
Endocrinology and Metabolism Clinics of North America, 2015
Identifying the correct cause of hyperprolactinemia is crucial for treatment. Prolactinoma is the most common pathologic cause of hyperprolactinemia. Dopamine agonists are efficacious in about 80% to 90% of patients with prolactinoma, leading to reduction of serum prolactin levels and tumor dimensions. Neurosurgery, mainly by the transsphenoidal route,
Andrea, Glezer, Marcello D, Bronstein
openaire +2 more sources
Identifying the correct cause of hyperprolactinemia is crucial for treatment. Prolactinoma is the most common pathologic cause of hyperprolactinemia. Dopamine agonists are efficacious in about 80% to 90% of patients with prolactinoma, leading to reduction of serum prolactin levels and tumor dimensions. Neurosurgery, mainly by the transsphenoidal route,
Andrea, Glezer, Marcello D, Bronstein
openaire +2 more sources
Endocrinology and Metabolism Clinics of North America, 1987
Prolactin-secreting pituitary tumors are not rare. The diagnosis of a patient with hyperprolactinemia and possible tumor should be carried out in an orderly fashion by first excluding secondary causes. If the patient has pathologic hyperprolactinemia, assessment of pituitary anatomy with a high resolution CT scan (or MRI) should be done.
M L, Vance, M O, Thorner
openaire +2 more sources
Prolactin-secreting pituitary tumors are not rare. The diagnosis of a patient with hyperprolactinemia and possible tumor should be carried out in an orderly fashion by first excluding secondary causes. If the patient has pathologic hyperprolactinemia, assessment of pituitary anatomy with a high resolution CT scan (or MRI) should be done.
M L, Vance, M O, Thorner
openaire +2 more sources
Neurosurgery, 1991
Abstract Six cases of malignant prolactinoma have been reported; an additional two cases are presented here and the literature is reviewed. Diagnosis rests upon evidence of metastasis rather than histological criteria perse. Cases have arisen from known adenomas, particularly the invasive type. Bromocriptine is a useful palliative.
E A, Popovic +5 more
openaire +2 more sources
Abstract Six cases of malignant prolactinoma have been reported; an additional two cases are presented here and the literature is reviewed. Diagnosis rests upon evidence of metastasis rather than histological criteria perse. Cases have arisen from known adenomas, particularly the invasive type. Bromocriptine is a useful palliative.
E A, Popovic +5 more
openaire +2 more sources
Clinical Endocrinology, 1995
SummaryBACKGROUND Apart from the rare association with type I multiple endocrine neoplasia (MEN‐1), familial types of prolactinoma have not been reported.PATIENTS AND MEASUREMENTS Eight hyperprolacti‐naemic patients in four families and 18 of their first and second‐degree relatives (parents, children and grandchildren) were examined.
M, Berezin, A, Karasik
openaire +2 more sources
SummaryBACKGROUND Apart from the rare association with type I multiple endocrine neoplasia (MEN‐1), familial types of prolactinoma have not been reported.PATIENTS AND MEASUREMENTS Eight hyperprolacti‐naemic patients in four families and 18 of their first and second‐degree relatives (parents, children and grandchildren) were examined.
M, Berezin, A, Karasik
openaire +2 more sources
Acta Endocrinologica, 1992
Malignant prolactinoma is a rare entity and only a few cases have been published. The diagnostic criteria and the clinical course remain unclear. We present a case of malignant prolactinoma in a woman with a 30-year duration of the disease. In the terminal stage of the disease the prolactinoma metastasized to the left eye, the prolactin level reaching ...
M, Berezin +4 more
openaire +2 more sources
Malignant prolactinoma is a rare entity and only a few cases have been published. The diagnostic criteria and the clinical course remain unclear. We present a case of malignant prolactinoma in a woman with a 30-year duration of the disease. In the terminal stage of the disease the prolactinoma metastasized to the left eye, the prolactin level reaching ...
M, Berezin +4 more
openaire +2 more sources
Annales d'Endocrinologie, 2007
Surgery is generally used as second-line treatment in prolactinomas. For microprolactinomas, it may be indicated in cases of resistance or intolerance to dopamine agonists or where patients prefer definitive cure to lifelong drug treatment. In highly trained hands, selective adenomectomy results in normalization of prolactin levels in 75-90% of cases ...
M, Jan, H, Dufour, T, Brue, P, Jaquet
openaire +2 more sources
Surgery is generally used as second-line treatment in prolactinomas. For microprolactinomas, it may be indicated in cases of resistance or intolerance to dopamine agonists or where patients prefer definitive cure to lifelong drug treatment. In highly trained hands, selective adenomectomy results in normalization of prolactin levels in 75-90% of cases ...
M, Jan, H, Dufour, T, Brue, P, Jaquet
openaire +2 more sources
Journal of Endocrinological Investigation, 2011
Prolactinomas are the most common hormonally active pituitary tumors and are usually successfully treated with dopamine agonists. A small proportion, however, appears not to respond to such treatment and such cases are termed resistant prolactinomas. Resistance is generally defined as failure to achieve normoprolactinemia and inability to induce tumor ...
Vasilev, Vladimir +4 more
openaire +3 more sources
Prolactinomas are the most common hormonally active pituitary tumors and are usually successfully treated with dopamine agonists. A small proportion, however, appears not to respond to such treatment and such cases are termed resistant prolactinomas. Resistance is generally defined as failure to achieve normoprolactinemia and inability to induce tumor ...
Vasilev, Vladimir +4 more
openaire +3 more sources
Pituitary, 2005
In recent years the demonstration that human pituitary adenomas are monoclonal in origin provides further evidence that pituitary neoplasia arise from the replication of a single mutated cell in which growth advantage results from either activation of proto-oncogenes or inactivation of tumor suppressor genes.
Spada A., Mantovani G., Lania A.
openaire +3 more sources
In recent years the demonstration that human pituitary adenomas are monoclonal in origin provides further evidence that pituitary neoplasia arise from the replication of a single mutated cell in which growth advantage results from either activation of proto-oncogenes or inactivation of tumor suppressor genes.
Spada A., Mantovani G., Lania A.
openaire +3 more sources